Abstract
Objectives: In this study, we aimed to assess the value of admission time CBC parameters in predicting post-primary PCI corrected TIMI frame count.
Background: Recent years have witnessed a large series of studies evaluating different laboratory variables to predict no-reflow phenomenon following primary PCI (PPCI) in patients with STEMI. However, a general agreement about the most reliable predictor of the no-reflow phenomenon is challenging and also intriguing.
Methods: The current study concluded 208 consecutive patients who underwent primary PCI for ST-Elevation Myocardial Infarction (STEMI) from January 2014 to February 2016. Blood samples were obtained after taking ECG. Complete blood samples were collected and analyzed within 5 minutes from sampling. Post-PCI corrected Thrombolysis in Myocardial Infarction (TIMI) frame count was determined by one interventional cardiologist blinded to patients’ clinical data. The correlation between admission time blood parameters and post-primary PCI corrected TIMI frame count in patients with STEMI were assessed.
Results: Corrected TIMI frame count was positively correlated with WBC count (R: 0.18, P-value: <0.01), neutrophil count (R: 0.34, P-value: <0.01), and platelet count (R: 0.23, P-value: <0.01) and negatively correlated with lymphocyte count (R: -0.2, P-value: <0.01). Multiple linear regression results demonstrated that corrected TIMI frame count was positively correlated with neutrophil count (P < 0·001) and platelet count (P < 0·001) and negatively correlated with lymphocyte count (p=0.004).
Conclusion: High counts of WBC, neutrophil, and platelet and low count of lymphocyte may be predictors of no-reflow in STEMI patients undergoing PPCI. The clinical significance of such predictive parameters becomes clear as we consider the treatment approach in STEMI patients. Appropriate risk stratification leads to better treatment planning and allocation of resources.
Keywords: Myocardial infarction, ST elevation myocardial infarction, percutaneous coronary intervention, blood cell count, no-reflow phenomenon, angioplasty.
Graphical Abstract
Cardiovascular & Hematological Disorders-Drug Targets
Title:Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Volume: 20 Issue: 3
Author(s): Hossein Vakili, Isa Khaheshi*, Amirsina Sharifi, Negin Nickdoost, Mohammad H. Namazi, Morteza Safi , Habibollah Saadat, Saeed A. Parsa, Mohammad A. Akbarzadeh, Mohammadreza Naderian, Negin Yousefi, Mahin Shirazi and Mohammadreza Tabary
Affiliation:
- Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Myocardial infarction, ST elevation myocardial infarction, percutaneous coronary intervention, blood cell count, no-reflow phenomenon, angioplasty.
Abstract:
Objectives: In this study, we aimed to assess the value of admission time CBC parameters in predicting post-primary PCI corrected TIMI frame count.
Background: Recent years have witnessed a large series of studies evaluating different laboratory variables to predict no-reflow phenomenon following primary PCI (PPCI) in patients with STEMI. However, a general agreement about the most reliable predictor of the no-reflow phenomenon is challenging and also intriguing.
Methods: The current study concluded 208 consecutive patients who underwent primary PCI for ST-Elevation Myocardial Infarction (STEMI) from January 2014 to February 2016. Blood samples were obtained after taking ECG. Complete blood samples were collected and analyzed within 5 minutes from sampling. Post-PCI corrected Thrombolysis in Myocardial Infarction (TIMI) frame count was determined by one interventional cardiologist blinded to patients’ clinical data. The correlation between admission time blood parameters and post-primary PCI corrected TIMI frame count in patients with STEMI were assessed.
Results: Corrected TIMI frame count was positively correlated with WBC count (R: 0.18, P-value: <0.01), neutrophil count (R: 0.34, P-value: <0.01), and platelet count (R: 0.23, P-value: <0.01) and negatively correlated with lymphocyte count (R: -0.2, P-value: <0.01). Multiple linear regression results demonstrated that corrected TIMI frame count was positively correlated with neutrophil count (P < 0·001) and platelet count (P < 0·001) and negatively correlated with lymphocyte count (p=0.004).
Conclusion: High counts of WBC, neutrophil, and platelet and low count of lymphocyte may be predictors of no-reflow in STEMI patients undergoing PPCI. The clinical significance of such predictive parameters becomes clear as we consider the treatment approach in STEMI patients. Appropriate risk stratification leads to better treatment planning and allocation of resources.
Export Options
About this article
Cite this article as:
Vakili Hossein , Khaheshi Isa *, Sharifi Amirsina , Nickdoost Negin , Namazi H. Mohammad , Safi Morteza, Saadat Habibollah , Parsa A. Saeed , Akbarzadeh A. Mohammad , Naderian Mohammadreza , Yousefi Negin , Shirazi Mahin and Tabary Mohammadreza , Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction, Cardiovascular & Hematological Disorders-Drug Targets 2020; 20 (3) . https://dx.doi.org/10.2174/1871529X20666200206123118
DOI https://dx.doi.org/10.2174/1871529X20666200206123118 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design The Rabbit as an Experimental and Production Animal: From Genomics to Proteomics
Current Protein & Peptide Science Peripheral Heart Blocks Associated with Myocardial Infarcts: Clinical Diagnosis Based on Experimental Findings
Current Cardiology Reviews Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Cardiac Protection by Volatile Anaesthetics: A Review
Current Vascular Pharmacology The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design A Comprehensive Systemic Literature Review of Pericardial Decompression Syndrome: Often Unrecognized and Potentially Fatal Syndrome
Current Cardiology Reviews Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology ATP-Sensitive Potassium Channels
Current Pharmaceutical Design A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Preconditioning of the Myocardium by Volatile Anesthetics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Diagnosis and Management of Chronic Coronary Artery Disease
Current Cardiology Reviews Pharmacological Pre- and Post- Conditioning Agents: Reperfusion-Injury of the Heart Revisited
Mini-Reviews in Medicinal Chemistry Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology Opioid-induced Cardioprotection
Current Pharmaceutical Design Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Halogenated Agents and Cardiovascular Surgery: Has Mortality Really Decreased?
Current Vascular Pharmacology